A certain class of oral drugs used to treat type 2 diabetes can double the risk of heart failure in patients, warn a group of group of researchers led by an Indian origin researcher.
Sonal Singh, assistant professor of internal medicine, and Curt D. Furberg, M.D., Ph.D., professor of public health sciences, from Wake Forest University School of Medicine faculty members have said that thiazolidinediones can exacerbate heart attack risk.
Advertisement
Rosiglitazone and pioglitazone are the two major thiazolidinediones given to control diabetes by lowering blood sugar levels.
"We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," wrote experts.
"At this time, justification for use of thiazolidinediones is very weak to non-existent," they added.
Singh and Furberg said that diabetics have high blood pressure, cholesterol and triglyceride levels, which "further compound their already increased risk of developing ischemic heart disease."
Heart disease and high blood pressure "represent conditions that are major precursors of congestive heart failure."
An analysis of four long-term trials, using rosiglitazone, showed that it doubled heart failure risk among the diabetes patients.
They said that results from three large randomized clinical trials earlier failed to demonstrate that intensive control of blood sugar reduces mortality or events from cardiovascular disease in patients with type 2 diabetes.
Source: ANI
SRM
Advertisement
"At this time, justification for use of thiazolidinediones is very weak to non-existent," they added.
Singh and Furberg said that diabetics have high blood pressure, cholesterol and triglyceride levels, which "further compound their already increased risk of developing ischemic heart disease."
Heart disease and high blood pressure "represent conditions that are major precursors of congestive heart failure."
An analysis of four long-term trials, using rosiglitazone, showed that it doubled heart failure risk among the diabetes patients.
They said that results from three large randomized clinical trials earlier failed to demonstrate that intensive control of blood sugar reduces mortality or events from cardiovascular disease in patients with type 2 diabetes.
Source: ANI
SRM
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.